Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00442312|
Recruitment Status : Unknown
Verified February 2007 by Genovate Biotechnology Co., Ltd.,.
Recruitment status was: Active, not recruiting
First Posted : March 1, 2007
Last Update Posted : March 1, 2007
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This study is to evaluate the efficacy and safety of Combigan ophthalmic solution in combination with Latanoprost when the therapy is swiched from Latanoprost monotherapy in patient with Glaucoma or ocular hypertension.
- Combigan Ophthalmic Solution provides addition IOP loweringwhen combined with Latanoprost.
- The treatment with Combigan Ophthalmic Solution has an acceptable safety profile, as measured by ocular and systemic safety parameters.
|Condition or disease||Intervention/treatment||Phase|
|Glaucoma||Drug: Combigan Ophthalmic Solutiom||Phase 4|
The purpose of this study is to comparethe efficacy and safety Ophthalmic Solution in combination with Latanoprost when the therapy is swiched from Latanoprost monotherapy in patient with Glaucoma or ocular hypertension.
The study will be open label, prospective, multi-centered where patients will be swiched from Latanoprostmonotherapy to a combination therapy of Latanoprost with Combigan Ophthalmic Solution.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||43 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension.|
|Study Start Date :||May 2006|
|Study Completion Date :||November 2006|
- The change of IntraOcular Pressure From baseline to week 12
- The change of IntraOcular Pressure on week 8.
- The change of IntraOcular Pressure on week 12
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||20 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or female, of legal age of consent.
- Diagnosis of ocular hypertension (OHT) or glaucoma (incl. open angle glaucoma, chronic angle closure glaucoma, exfoliative glaucoma, pigmentary glaucoma or pseudophakic glaucoma) and requiring administration of IOP lowering eye drops.
- Written informed consent has been obtained.
- The patient can understand all study instructions, and is willing and able to comply with the schedule of visits and treatment.
- Patient has been administering latanoprost eye drops as monotherapy in affected eye(s) for at least 12 weeks according to the approved product labeling.
- Patient's Day 0 IOP > 18 mm Hg in the proposed study eye/s on established latanoprost therapy.
- Patients who have used COMBIGAN® Ophthalmic Solution in the past must not have been discontinued from using this medication due to adverse events or due to lack of efficacy.
- Day 0: negative urine pregnancy test for females of childbearing potential.
- .Uncontrolled systemic disease (e.g., hypertension, diabetes).
- .Females who are pregnant, nursing, or planning a pregnancy, or females of childbearing potential who are not using a reliable means of contraception. A female is considered of child-bearing potential unless she is post-menopausal, without a uterus and/or both ovaries, or has a tubal-ligation.
- .Known allergy or hypersensitivity to the study medication or components.
- .Anticipated alteration of existing chronic therapy with agents which could have a substantial effect on IOP (including, but not necessarily limited to systemic adrenergic agents including beta-adrenergic blocking agents [e.g., propanolol, metoprolol, nadolol, timolol and atenolol]), substantial interaction with study medications, or interaction with study outcomes.
- .Corneal abnormalities that would preclude accurate IOP readings with an applanation tonometer.
- .Any other active ocular disease other than glaucoma or ocular hypertension (e.g., uveitis, ocular infections, or severe dry eye). However, patients with chronic mild blepharitis, cataract, age-related macular degeneration, or a background diabetic retinopathy can be enrolled at the discretion of the investigator.
- .Required chronic use of other ocular medications during the study other than the study medications. Occasional use of artificial tears or topical decongestants and/or antihistamine is acceptable. Use of these within 24 hours of a scheduled study visit is prohibited.
- .Ocular surgery within the past 3 months.
- .Current enrolment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.
- .Patient has a condition or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study,
- .Day 0 - Significant ocular irritation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00442312
|Principal Investigator:||Da-Wen Lu||Tri-Service General Hospital, Taiwan ROC|
|Other Study ID Numbers:||
|First Posted:||March 1, 2007 Key Record Dates|
|Last Update Posted:||March 1, 2007|
|Last Verified:||February 2007|
Brimonidine Tartrate, Timolol Maleate Drug Combination
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic alpha-2 Receptor Agonists